Karl J. D’Silva, MDDISCLOSURES Renal cell carcinoma (RCC) represents up to 85% of kidney cancers. It is considered the deadliest urologic cancer in the United States, with a 5-year survival rate of 76% overall, going down to only 12% for patients with late-stage disease. Here are five things that primary care clinicians should know about...
Tag: <span>Renal cell carcinoma</span>
Post
Novel allogeneic CAR T cell therapy delivers promising early results in patients with metastatic clear cell renal cell carcinoma
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER ORLANDO ― The CD70-targeting allogeneic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to results of a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center and presented...
Post
New possible cell target to treat clear cell renal cell carcinoma
by Perelman School of Medicine at the University of Pennsylvania Credit: Pixabay/CC0 Public Domain Clear cell renal cell carcinoma (ccRCC) cells can be destroyed and kept from multiplying by inhibiting the HDL cholesterol receptor SCARB1, according to research from the Perelman School of Medicine at the University of Pennsylvania. The scientists found the health of these specific cancer...
Post
Researchers uncover potentially promising therapeutic combination for renal cell carcinoma
by Beth Israel Deaconess Medical Center Credit: Pixabay/CC0 Public Domain Renal cell carcinoma (RCC) is the most common form of kidney cancer. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide. Currently, the 5-year survival rate for patients with metastatic RCC is only about 12 percent....